Endoxifen for the treatment of bipolar I disorder
US12245997B2 · kind B2 · utility
0Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 9, 2021 |
| Grant date | Mar 11, 2025 |
| Priority date | — |
| Expiry date | Apr 9, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2833
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for maintaining a therapeutically effective concentration of endoxifen for treatment of a patient with bipolar I disorder is provided. The said method includes administering to the patient, a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, the patient is not required to be administered rescue medication during the administration of the endoxifen citrate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.